… the potential for drug-drug interaction much earlier in the drug development program since
… to manage blood pressure, cardiovascular diseases, metabolic and digestive disorders, joint …

… key features of neurodegenerative diseases. Investigational … according to diseases and
stages of clinical development, so … of complex diseases such as neurodegeneration, namely ‘the …

… emerging disease-modifying therapeutic approaches against neurodegenerative diseases,
… The development of anti-misfolding and anti-aggregation agents that are commonly …

… technologies that have been adopted by top pharmaceutical companies looking to bridge
the gap between drug discovery and drug development in neurodegenerative disease. …

… for human iPSC technology in drug development. In this review we first summarize the
classical drug development pipeline for NDDs and discuss how iPSC-based drug screening can …

… drug development for ND diseases is a high-risk therapeutic area where only 12% of all the
drug … Most of these approved drugs (12%) can only decrease the disease symptoms to some …

… for disease-combating interventions will be developed through nanomedicine approaches.
First, the improvement of site-directed drug delivery in brain regions most affected by disease …

… The creation of a new drug to … drug development is low; 80% of drug clinical trials fail in
phase I or II, and only 1 in 5000 new drugs typically receives approval by the US Food and Drug …

… review advances in the development of assays and neurodegenerative disease models that
… neurodegeneration that can be used to discover drugs to treat neurodegenerative diseases. …

… In our annual update on the state of the AD drug development … in drug development, and
new trends in AD clinical trials. Our goal is to continuously learn from the drug development …